Clinical trial · Observational
Molecular Profiling Project
ATORG001 - Molecular Profiling Project
NCT04025515CI-TRIAL-00111208suspendedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Discussion under way on how to continue/restart the study in view of slow recruitment rate.
Summary
Brief summary (as posted)
In this study, the investigators plan to undertake comprehensive molecular profiling of "actionable" alterations in lung cancer specimens in order to determine the prevalence of each genetic subtype in the local population.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Non-Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Molecular profiling of lung cancer specimens
- timeFrame
- After patient meets the eligibility criteria and consent has been taken
- description
- Lung cancer specimens will be collected and profiled at a molecular level to evaluate the molecular epidemiology of NSCLC in Asia
Secondary outcomes (3)
- measure
- Collection of patient survival status
- timeFrame
- After molecular profiling has been completed, every few months up to 2 years
- measure
- Collection of subsequent patient treatment status
- timeFrame
- After molecular profiling has been completed, every few months up to 2 years
- measure
- Collection of the clinical outcomes of the subsequent treatments the patients receive
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 21 Years
Show eligibility criteria text
Inclusion Criteria: * The availability of sufficient archival tumor tissue specimen (15 slides of 4 microns per section) * Age ≥ 21 years * WHO performance status ≤ 2 * Life expectancy of ≥ 12 weeks * Patients should have adequate organ function for potential consideration into clinical trials (routine blood tests are valid within 14 days before enrollment): * Adequate bone marrow function as shown by: ANC ≥ 1.0 x 10\^9/L, Platelets ≥ 75 x 10\^9/L, Hb ≥ 7.5 g/dL * Alanine aminotransferase (ALT) and aspirate aminotransferase (AST) normal range (or ≤3.0 x ULN if liver metastases are present) * Willing to provide signed informed consent * Patients whom do not fulfill the above criteria may be discussed on a case-by-case basis with the study team, for potential enrolment Exclusion Criteria: \- No more than 3 lines of cytotoxic chemotherapy at the time of enrolment
References
Publications (0)
Data not yet available
No reference posted for this study.